NO20053185L - Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. - Google Patents

Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Info

Publication number
NO20053185L
NO20053185L NO20053185A NO20053185A NO20053185L NO 20053185 L NO20053185 L NO 20053185L NO 20053185 A NO20053185 A NO 20053185A NO 20053185 A NO20053185 A NO 20053185A NO 20053185 L NO20053185 L NO 20053185L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
attention
failure
attention failure
Prior art date
Application number
NO20053185A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053185D0 (no
Inventor
Jr Vincent Edward Groppi
Donn Gregory Wishka
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20053185D0 publication Critical patent/NO20053185D0/no
Publication of NO20053185L publication Critical patent/NO20053185L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20053185A 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse. NO20053185L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11
PCT/IB2003/005542 WO2004052461A1 (fr) 2002-12-11 2003-11-28 Traitement combine de troubles deficitaires de l'attention avec hyperactivite

Publications (2)

Publication Number Publication Date
NO20053185D0 NO20053185D0 (no) 2005-06-29
NO20053185L true NO20053185L (no) 2005-08-17

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053185A NO20053185L (no) 2002-12-11 2005-06-29 Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.

Country Status (23)

Country Link
US (1) US20050107425A1 (fr)
EP (1) EP1572300A1 (fr)
JP (1) JP2006510663A (fr)
KR (1) KR20050085538A (fr)
CN (1) CN1735441A (fr)
AP (1) AP2005003336A0 (fr)
AU (1) AU2003283656A1 (fr)
BR (1) BR0317229A (fr)
CA (1) CA2509142A1 (fr)
CO (1) CO5700801A2 (fr)
CR (1) CR7868A (fr)
EA (1) EA200500783A1 (fr)
EC (1) ECSP055852A (fr)
HR (1) HRP20050522A2 (fr)
IS (1) IS7858A (fr)
MA (1) MA27606A1 (fr)
MX (1) MXPA05006336A (fr)
NO (1) NO20053185L (fr)
OA (1) OA12969A (fr)
PL (1) PL377552A1 (fr)
TN (1) TNSN05158A1 (fr)
WO (1) WO2004052461A1 (fr)
ZA (1) ZA200504338B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP1735306A2 (fr) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR20100137473A (ko) * 2008-02-19 2010-12-30 아돌로 코포레이션 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
WO2012015715A1 (fr) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Dérivés de thiazol-2-ylamine substitués, compositions pharmaceutiques et procédés d'utilisation en tant que modulateurs de 11-bêta-hsd1
EP3461481A1 (fr) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Procédés de maintien, de traitement ou d'amélioration de la fonction cognitive
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (fr) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (fr) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 Composition pharmaceutique pour prévenir ou traiter un trouble déficitaire de l'attention avec hyperactivité

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
EA200500783A1 (ru) 2005-12-29
JP2006510663A (ja) 2006-03-30
CN1735441A (zh) 2006-02-15
MXPA05006336A (es) 2005-08-26
HRP20050522A2 (en) 2005-12-31
EP1572300A1 (fr) 2005-09-14
CR7868A (es) 2005-07-08
AU2003283656A1 (en) 2004-06-30
CO5700801A2 (es) 2006-11-30
AP2005003336A0 (en) 2005-06-30
ECSP055852A (es) 2005-09-20
KR20050085538A (ko) 2005-08-29
US20050107425A1 (en) 2005-05-19
NO20053185D0 (no) 2005-06-29
IS7858A (is) 2005-05-23
ZA200504338B (en) 2006-07-26
TNSN05158A1 (fr) 2007-05-14
BR0317229A (pt) 2005-11-01
MA27606A1 (fr) 2005-11-01
PL377552A1 (pl) 2006-02-06
OA12969A (en) 2006-10-13
WO2004052461A1 (fr) 2004-06-24
CA2509142A1 (fr) 2004-06-24

Similar Documents

Publication Publication Date Title
NO20053185L (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
NO20100077L (no) Behandling med alfa7-selektive ligander
NO20084004L (no) Monokolonne-FPSO
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
EA199900206A1 (ru) Способ лечения обычной простуды или аллергического ринита
ATE405670T1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
BRPI0515376A (pt) método para prevenir ou tratar diarréia em um mamìfero, composição útil na prevenção ou no tratamento de diarréia em um mamìfero, kit adequado para administrar um exopolissacarìdeo microbiano a um mamìfero, e, meio para comunicar informação
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
NO20081200L (no) Polyalkyleniminer og polyalkylenakrylamidsalt for syregass scrubbingprosess
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE409475T1 (de) Behandlung von fibromyalgie mit pindolol
WO2006012476A3 (fr) Procede de traitement des pathologies et des troubles du systeme nerveux
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE410235T1 (de) Behandlung von ballastwasser
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
NO20062700L (no) Morfolinderivater som norepinefrin reopptaksinhibitorer
ATE291920T1 (de) Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen